Anti-TIF1-γ-associated dermatomyositis associated with recurrent metastatic triple-negative breast cancer: Dramatic clinical response to sacituzumab govitecan

被引：0
|
作者：
Wang, Wei-Yao [1 ,2 ]
Lee, Chin-Yu [1 ,2 ]
Hu, Stephen Chu-Sung [1 ,2 ,3 ]
机构：
[1] Kaohsiung Med Univ Hosp, Dept Dermatol, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Dept Dermatol, Kaohsiung, Taiwan
[3] Kaohsiung Municipal Siaogang Hosp, Dept Dermatol, Kaohsiung, Taiwan
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2024年 / 22卷 / 07期
关键词：
Anti-transcriptional intermediary factor 1 gamma antibody; breast cancer; dermatomyositis; paraneoplastic syndrome; sacituzumab govitecan; AUTOANTIBODIES;
D O I：
10.1111/ddg.15399
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1008 / 1011
页数：4
相关论文
共 50 条
  • [1] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [2] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [3] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [4] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
  • [5] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Spring, Laura M.
    Nakajima, Erika
    Hutchinson, Jennifer
    Viscosi, Elene
    Blouin, Gayle
    Weekes, Colin
    Rugo, Hope
    Moy, Beverly
    Bardia, Aditya
    ONCOLOGIST, 2021, 26 (10): : 827 - 834
  • [6] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [7] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [8] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [9] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [10] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Cheng, Shao-Xian
    Chen, Qiu-Chi
    Lin, Guo-He
    Han, Yan-Hong
    Wang, Bi-Cheng
    Dai, Yi
    Zhao, Yan-Xia
    MEDICINE, 2023, 102 (30) : E34486
12345